{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T07:30:43Z","timestamp":1790062243614,"version":"4.0.1"},"reference-count":33,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2010,9,1]],"date-time":"2010-09-01T00:00:00Z","timestamp":1283299200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2010,9]]},"DOI":"10.1016\/j.thromres.2010.05.019","type":"journal-article","created":{"date-parts":[[2010,6,11]],"date-time":"2010-06-11T10:24:12Z","timestamp":1276251852000},"page":"207-210","source":"Crossref","is-referenced-by-count":9,"title":["The plasma levels of activated thrombin activatable fibrinolysis inhibitor and thrombomodulin in Beh\u00e7et Disease and their association with thrombosis"],"prefix":"10.1016","volume":"126","author":[{"given":"Ayhan","family":"Donmez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenan","family":"Aksu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hakan","family":"Ayd\u0131n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gokhan","family":"Keser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seckin","family":"Cagirgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eker","family":"Doganavsargil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murat","family":"Tombuloglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.thromres.2010.05.019_bib1","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.berh.2008.08.005","article-title":"Beh\u00e7et's syndrome","volume":"22","author":"Yurdakul","year":"2008","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.thromres.2010.05.019_bib2","first-page":"402","article-title":"Vascular involvement in Beh\u00e7et's disease","volume":"19","author":"Koc","year":"1992","journal-title":"J Rheumatol"},{"key":"10.1016\/j.thromres.2010.05.019_bib3","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1093\/rheumatology\/40.6.652","article-title":"Thrombosis in Beh\u00e7et's disease: a retrospective survey from a single UK centre","volume":"40","author":"Ames","year":"2001","journal-title":"Rheumatology"},{"key":"10.1016\/j.thromres.2010.05.019_bib4","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1046\/j.1365-2796.1996.396853000.x","article-title":"Impaired haemostatic kinetics and endothelial function in Beh\u00e7et's disease","volume":"240","author":"Haznedaroglu","year":"1996","journal-title":"J Intern Med"},{"key":"10.1016\/j.thromres.2010.05.019_bib5","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0735-1097(00)01137-2","article-title":"Vascular endothelial function and oxidative stress mechanisms in patients with Beh\u00e7et's syndrome","volume":"37","author":"Chambers","year":"2001","journal-title":"J Am Coll Cardiol"},{"issue":"Suppl24","key":"10.1016\/j.thromres.2010.05.019_bib6","first-page":"25","article-title":"Interactions of nitric oxide and superoxide dismutase in Beh\u00e7et's disease","volume":"19","author":"Kiraz","year":"2001","journal-title":"Clin Exp Rheumatol"},{"issue":"6","key":"10.1016\/j.thromres.2010.05.019_bib7","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1093\/rheumatology\/40.6.687","article-title":"Hyperhomocysteinaemia in Behcet's disease","volume":"40","author":"Aksu","year":"2001","journal-title":"Rheumatology"},{"key":"10.1016\/j.thromres.2010.05.019_bib8","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0049-3848(02)00006-3","article-title":"Pathological haemostasis and \u2018prothrombotic state\u2019 in Beh\u00e7et's disease","volume":"105","author":"Kiraz","year":"2002","journal-title":"Thromb Res"},{"key":"10.1016\/j.thromres.2010.05.019_bib9","first-page":"496","article-title":"Factor V Leiden mutation in patients with Beh\u00e7et's disease","volume":"25","author":"Oner","year":"1998","journal-title":"J Rheumatol"},{"key":"10.1016\/j.thromres.2010.05.019_bib10","first-page":"2849","article-title":"Effects of factor V gene G1691A, methylenetetrahydrofolate reductase gene C677T, and prothrombin gene G20210A mutations on deep venous thrombosis in Beh\u00e7et's disease","volume":"27","author":"Toydemir","year":"2000","journal-title":"J Rheumatol"},{"key":"10.1016\/j.thromres.2010.05.019_bib11","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1001\/archopht.1985.01050070061030","article-title":"Plasminogen activator activity levels in patients with Beh\u00e7et's syndrome","volume":"103","author":"Mishima","year":"1985","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.thromres.2010.05.019_bib12","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1159\/000040847","article-title":"Haemostasis, thrombosis, and endothelium in Beh\u00e7et's disease","volume":"99","author":"Haznedaroglu","year":"1998","journal-title":"Acta Haematol"},{"key":"10.1016\/j.thromres.2010.05.019_bib13","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1046\/j.1538-7836.2003.00329.x","article-title":"Thrombin-activatable fibrinolysis inhibitor (TAFI, plasma procarboxypeptidase B, procarboxypeptidase R, procarboxypeptidase U)","volume":"1","author":"Bouma","year":"2003","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.thromres.2010.05.019_bib14","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2174\/1568006013337999","article-title":"Thrombin Activable Fibrinolysis Inhibitor (TAFI): Molecular Genetics of an Emerging Potential Risk Factor for Thrombotic Disorders","volume":"1","author":"Boffa","year":"2001","journal-title":"Curr Drug Targets Cardiovasc Haematol Disord"},{"key":"10.1016\/j.thromres.2010.05.019_bib15","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.1182\/blood.V95.9.2855.009k02_2855_2859","article-title":"Thrombin Activable Fibrinolysis Inhibitor and the risk for deep vein thrombosis","volume":"95","author":"Van Tilburg","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2010.05.019_bib16","doi-asserted-by":"crossref","first-page":"16603","DOI":"10.1074\/jbc.271.28.16603","article-title":"TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex","volume":"271","author":"Bajzar","year":"1996","journal-title":"J Biol Chem"},{"issue":"4","key":"10.1016\/j.thromres.2010.05.019_bib17","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.thromres.2004.09.010","article-title":"Thrombin activatable fibrinolysis inhibitor in Behcet's disease","volume":"115","author":"Donmez","year":"2005","journal-title":"Thromb Res"},{"key":"10.1016\/j.thromres.2010.05.019_bib18","first-page":"267","article-title":"Plasma thrombin activatable fibrinolysis inhibitor levels in Behcet's disease","volume":"37","author":"Ozcan","year":"2007","journal-title":"Turk J Med Sci"},{"issue":"5","key":"10.1016\/j.thromres.2010.05.019_bib19","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1111\/j.1365-2141.2008.07078.x","article-title":"Fibrinolytic inhibitor levels and polymorphisms in Beh\u00e7et disease and their association with thrombosis","volume":"141","author":"Ricart","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1016\/j.thromres.2010.05.019_bib20","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1093\/rheumatology\/31.5.299","article-title":"Evaluation of diagnostics (\u2018classification\u2019) criteria in Beh\u00e7et's disease-towards internationally agreed criteria","volume":"31","author":"International Study Group for Beh\u00e7et's Disease","year":"1992","journal-title":"Br J Rheumatol"},{"key":"10.1016\/j.thromres.2010.05.019_bib21","first-page":"1033","article-title":"Beh\u00e7et's disease in Israel: the influence of ethnic origin on disease expression and severity","volume":"28","author":"Krause","year":"2001","journal-title":"J Rheumatol"},{"key":"10.1016\/j.thromres.2010.05.019_bib22","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1007\/s00296-003-0302-7","article-title":"Plasma thrombomodulin levels in patients with Beh\u00e7et's disease","volume":"23","author":"Duzgun","year":"2003","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.thromres.2010.05.019_bib23","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1055\/s-0038-1650405","article-title":"Circulating thrombomodulin as a clue of endothelial damage in Beh\u00e7et's disease","volume":"75","author":"Haznedaroglu","year":"1996","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.thromres.2010.05.019_bib24","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1159\/000157397","article-title":"Soluble thrombomodulin and fibrinolysis in Beh\u00e7et's disease","volume":"5","author":"Ozcebe","year":"1996","journal-title":"Med Princ Pract"},{"key":"10.1016\/j.thromres.2010.05.019_bib25","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0002-9343(01)01048-8","article-title":"Vascular involvement in Beh\u00e7et's disease: relation with thrombophilic factors, coagulation activation and thrombomodulin","volume":"112","author":"Espinosa","year":"2002","journal-title":"Am J Med"},{"key":"10.1016\/j.thromres.2010.05.019_bib26","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1007\/BF01451044","article-title":"Thrombomodulin levels in Beh\u00e7et's disease with and without factor Leiden mutation","volume":"17","author":"Gurgey","year":"1998","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.thromres.2010.05.019_bib27","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1053\/ejvs.2000.1091","article-title":"Haemostasis in patients with Beh\u00e7et's disease","volume":"19","author":"Demirer","year":"2000","journal-title":"Eur J Vasc Endovasc Surg"},{"issue":"4","key":"10.1016\/j.thromres.2010.05.019_bib28","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1111\/j.1365-2141.2004.05072.x","article-title":"Activated protein C levels in Beh\u00e7et's disease and risk of venous thrombosis","volume":"125","author":"Navarro","year":"2004","journal-title":"Br J Haematol"},{"key":"10.1016\/j.thromres.2010.05.019_bib29","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1182\/blood.V76.10.2024.2024","article-title":"Plasma thrombomodulin in health and diseases","volume":"76","author":"Takano","year":"1990","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2010.05.019_bib30","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1093\/ajcp\/101.1.109","article-title":"Plasma thrombomodulin as a marker of vascular injuries in collagen vascular diseases","volume":"101","author":"Odhama","year":"1994","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.thromres.2010.05.019_bib31","first-page":"59","article-title":"Clinical significance of serum thrombomodulin levels in patients with systemic rheumatic diseases","volume":"15","author":"Kotajima","year":"1997","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.thromres.2010.05.019_bib32","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1007\/s00296-005-0590-1","article-title":"Endothelial functions in Beh\u00e7et's disease","volume":"26","author":"Kay\u0131kc\u0131oglu","year":"2006","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.thromres.2010.05.019_bib33","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1093\/rheumatology\/35.11.1178","article-title":"Coagulation factor V gene mutation increases the risk of venous thrombosis in Beh\u00e7et's disease","volume":"35","author":"Gul","year":"1996","journal-title":"Br J Rheumatol"}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384810003026?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384810003026?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,6,5]],"date-time":"2020-06-05T17:13:42Z","timestamp":1591377222000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384810003026"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,9]]}},"alternative-id":["S0049384810003026"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2010.05.019","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2010,9]]}}}